Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

B. Leeneman, C.A. Uyl-de Groot, M.J.B. Aarts, A.C.J. van Akkooi, F.W.P.J. van den Berkmortel, A.J.M. van den Eertwegh, J.W.B. de Groot, K.H. Herbschleb, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M.W.J.M. Wouters, J.B.A.G. Haanen, M.G. Franken

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number1003
Number of pages11
JournalCancers
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Keywords

  • metastatic melanoma
  • healthcare costs
  • real-world data
  • immunotherapy
  • targeted therapy

Cite this